The Turkish Competition Authority grants no exemption to the envisaged selective distribution system of a pharmaceutical company (Johnson&Johnson)

The Turkish Competition Board (“TCB“) has recently issued a no-go decision for the envisaged selective distribution system of Johnson&Johnson Sıh. Mal. San. ve Tic. Ltd. Şti. (“Johnson”) [1]. The decision concerns Johnson’s application before the Turkish Competition Authority (“TCA”) for an individual exemption to be granted to the “Human Pharmaceutical Warehouse Sales Agreement“ (“Agreement”) planned to be concluded with 9 (nine) pharmaceutical warehouses. The Agreement was related to the distribution of certain human medicine owned by Johnson (namely, Darzalex, Imbruvica, Stelara and Zytiga) and used for the treatment of serious illnesses, particularly, Darzalex and Imbruvica are used for the treatment of orphan diseases, by only 9 (nine) pharmaceutical warehouses. To that end, it was

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • ACTECON (Istanbul)
  • ACTECON (Istanbul)

Citation

Mert Kudat, Esen Ergül, The Turkish Competition Authority grants no exemption to the envisaged selective distribution system of a pharmaceutical company (Johnson&Johnson), 3 septembre 2020, e-Competitions September 2020, Art. N° 99600

Visites 63

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues